<DOC>
	<DOCNO>NCT02121483</DOCNO>
	<brief_summary>The aim study generate pharmacokinetic pharmacodynamic data identify safe-effective dose empagliflozin child adolescent age 10 less 18 year type 2 diabetes mellitus .</brief_summary>
	<brief_title>Pharmacokinetic Single Dose Trial Empagliflozin Children Adolescents With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Children adolescents type 2 diabetes mellitus Insufficient glycaemic control ( HbA1c &lt; =10.5 % ) despite diet exercise and/or metformin and/or stable basal MDI insulin Negative Islet Cell Antigen Glutamic Acid Decarboxylase autoantibodies fast Cpeptide level &gt; = 0.85 ng/ml BMI &gt; 50th percentile age sex Exclusion criterion : Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/l ) History acute metabolic decompensation diabetic ketoacidosis within 3 month screen visit exception acute decompensation time type 2 diabetes diagnosis Treatment weight reduction medication within 4 week randomisation</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>